Clinical trial · Interventional
A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer
NCT01836120CI-TRIAL-00010096unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A study of Raltitrexed plus Docetaxel versus Docetaxel as second-line chemotherapy in subjects with Gastric Cancer.The purpose of this study is to compare the activity of Raltitrexed plus Docetaxel versus Docetaxel as second-line chemotherapy in subjects with gastric carcinoma by estimating progression free survival (PFS) in each treatment arm.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Docetaxel | Drug | Docetaxel | ALIAS |
| Raltitrexed plus Docetaxel | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Raltitrexed plus Docetaxel
- interventionNames
- Drug: Raltitrexed plus Docetaxel
- type
- ACTIVE_COMPARATOR
- label
- Docetaxel
- interventionNames
- Drug: Docetaxel
Primary outcomes (1)
- measure
- Progression-free survival (PFS)
- timeFrame
- 1 years
Secondary outcomes (2)
- measure
- Objective Response Rate (ORR)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Signed informed consent form 2. Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-2; 3. Histologically or cytologically confirmed gastric cancer; 4. The first-line chemotherapy failure (required containing 5-fluorouracil) 5. At least have one measurable disease(according to RECIST, Response Evaluation Criteria in Solid Tumors ) 6. Life expectancy of at least 3 months; Exclusion Criteria: 1. Received any prior treatment including Raltitrexed; 2. Active or uncontrolled infection; 3. Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial; 4. Pregnant or lactating women.
References
Publications (0)
Data not yet available
No reference posted for this study.